India, May 13 -- Tuesday, iTeos Therapeutics, Inc. (ITOS) along with its development partner GSK announced the decision to discontinue the belrestotug development program and end the collaboration.
The decision comes after the announcement of the interim analysis of GALAXIES Lung-201, the Phase 2 platform study assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.
The company stated that the analysis did not meet established criteria for clinically meaningful improvements in the secondary endpoint of progression free survival in the belrestotug + dostarlimab combination cohorts versus dostarlimab monotherapy.
Additionally, an interim an...